
Arthroplasty
Combination of intravenous and topical TXA improves outcomes following primary TKA
J Arthroplasty. 2014 Dec;29(12):2342-6.184 patients undergoing unilateral total knee arthroplasty (TKA) were randomized to one of two tranexamic acid groups: an intravenous administration group, or a combined topical and intravenous administration group. Patients in the intravenous group were given 3g of tranexamic acid (TXA) intravenously during surgery. Those in the combined group had a solution composed of 1.5g of TXA and 50mL of normal saline irrigated into the wound after component implantation, and were also given 1.5g of TXA intravenously during surgery. Factors such as blood loss, transfusion rate, swelling ratio, and pain were assessed and compared between groups in the perioperative period up to 4 days. The results demonstrated significant effects of combined administration on maximum hemoglobin drop, postoperative blood loss to drain, pain on postoperative days 2-3, swelling on postoperative days 2-4, and satisfaction upon discharge.
Unlock the full article
Get unlimited access to OrthoEvidence with a free trial
Start TrialCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or continue reading this full article
Register Now

Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.